Lilly’s Failed Solanezumab: Could It Get Another Chance In A ‘Silicon Valley’ FDA?
Executive Summary
Alzheimer drug’s development was discontinued after third disappointing Phase III trial, but given the kind of FDA commissioner candidates getting meetings with the President, maybe Lilly should reconsider.